D. Yamasoba

This study characterizes the virological features of the SARS-CoV-2 Omicron XBB.1.16 variant, showing increased transmissibility and immune evasion compared to previous variants.

This study compares the pathogenicity of SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.5, finding BA.5 is more fusogenic and induces stronger inflammation than earlier variants.

This study investigates the virological characteristics of SARS-CoV-2 Omicron BA.2.75, finding it has higher transmissibility and pathogenicity compared to BA.2 and BA.5, but similar sensitivity to antiviral drugs.

This study analyzes the virological characteristics of SARS-CoV-2 Omicron variants BA.2.12.1, BA.4, and BA.5, finding they have higher reproduction numbers, reduced neutralization by prior immunity, increased replication in lung cells, and greater pathogenicity in hamsters compared to BA.2.

This study evaluates the sensitivity of new Omicron subvariants to eight therapeutic monoclonal antibodies, finding increased resistance in BA.4/5 to cilgavimab compared to BA.2.

This study identifies the S375F mutation in the Omicron spike protein as responsible for its reduced cleavage efficiency, fusogenicity, and rapid spread.

This study compares the virological characteristics of SARS-CoV-2 BA.2 and BA.1 variants, finding BA.2 has higher transmissibility, different antigenicity, greater replicative capacity, and higher pathogenicity in hamsters.

This study investigates the immune escape, infectivity, and cell-cell fusion properties of SARS-CoV-2 Omicron BA.1 compared to Delta, showing higher ACE2 affinity and antibody evasion but similar antiviral drug efficacy.

The paper investigates the SARS-CoV-2 Lambda variant, finding it more infectious due to specific mutations and better immune evasion, contributing to its spread in South America.